Portman, McCaskill Announce PSI Review of EpiPen Drug Pricing

FOR IMMEDIATE RELEASE: September 7, 2016
MEDIA CONTACTS: Kevin Smith (Portman) | 202-224-5190

John LaBombard (McCaskill) | 202-228-6263


Portman, McCaskill Announce PSI Review of EpiPen Drug Pricing 

Washington, D.C. – In their role as Chairman and Ranking Member of the U.S. Senate Permanent Subcommittee on Investigations, Senator Rob Portman (R-OH) and Senator Claire McCaskill (D-MO) made the following announcement today: 

“The Permanent Subcommittee on Investigations has opened a preliminary inquiry concerning Mylan Pharmaceuticals’ pricing and competition practices with respect to the EpiPen. Our review of this matter will be robust, thorough, and bipartisan. Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases.”